No relationship at all. Trof is a company maker for NEU. Successful P3 delivers over $100m in revenue from Acadia alone, against a market cap of $275m, add cash revenue from the sale of rights to the ROW and on-going royalties therefrom. Apply any reasonable PE ratio to that income and you come up with an enterprise value of 5 to 20 times where we are today not including the potential of the other molecule and other illnesses possibly addressed.
What is Trof to Acadia? One drug, in one market, approved for the treatment of one syndrome. It will be nice to have but it will hardly move the needle for them.
ACADIA & NEU charts YTD, page-4
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.01 |
Change
-1.640(8.79%) |
Mkt cap ! $2.174B | |||
| Open | High | Low | Value | Volume |
| $18.15 | $18.18 | $16.87 | $19.94M | 1.159M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 5090 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.10 | 995 | 1 |
View Market Depth
| Last trade - 16.10pm 05/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |